HIV and liver illnes

Although sex transfer of HCV is not efficient, 10% of acutely infected HCV persons report no danger element other than reproductive contact with an Infected partner. Many centers have reported an increase in acute HCV in MSM, and rates of sexual transmission of HCV appear to be higher in in MSM than in the general populace, especially among persons who are co infected with HIV. The natural representation of HCV infection is variable. Approximately 20% of mono infected patients ultimately develop cirrhosis, whereas approximately 80% of patients develop some degree of fibrosis (without progression to cirrhosis); patients without cirrhosis typically remain asymptomatic. HCV can affect organ systems outside the liver, such as dermatological and renal systems, but its effects most commonly are limited to the liver. Co infection with HIV adversely impacts the natural history of HCV infection. HIV/HCV-coinfected patients have reduce rates of spontaneous HCV clearance, higher HCV viral loads, drop rates of successful HCV treatment, faster progression to cirrhosis, and greater risk of developing liver compensation, end-stage liver illness and extracellular carcinoma (HCC). On the other hand, HCV confection does not appear to increase HIV- and AIDS-related complications or the happy result of HIV antiviral (ARV) treatment. Newly available directly acting anti-HCV drugs, when used in conjunction with model HCV therapy, appear to substantially enhance the likelihood of successfully treating HCV in challenging subgroups of co infected persons; these and additional new drugs that are in advanced stages of happening offer the hope of greatly improved therapies for HCV.